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ABSTRACT 
Introduction: Clopidogrel is an antiplatelet
agent converted to its active metabolite by
cytochrome P-450 isoenzymes. Numerous
drugs are known to inhibit P-450 isoen-
zymes, including proton pump inhibitors
(PPIs), which are often associated with
aspirin and clopidogrel to prevent adverse
gastrointestinal effects. In vitro studies first
showed that PPIs reduced the antiplatelet
effect of clopidogrel, while recent clinical
studies have raised concerns that the addi-
tion of a PPI to clopidogrel in acute coro-
nary syndrome (ACS) patients could actual-
ly increase the risk of recurrent cardiovas-
cular events.
Objective: The aim of this study was to eval-
uate whether the prescription of a PPI con-
ferred a worse prognosis in patients dis-
charged with aspirin and clopidogrel treat-
ment after ACS.
Methods: A total of 876 patients admitted
with ACS and discharged with aspirin and
clopidogrel, with a planned duration of at
least six months, from January 2004 to
March 2008, were reviewed. Patients were
classified in two groups according to
whether or not a PPI was prescribed at dis-
charge. The PPIs considered were those
mainly metabolized by cytochrome P-450
2C19. We excluded patients with insuffi-
cient information available on either pre-
scription or clinical records that could allow
Inibidores da bomba de protões em
doentes tratados com aspirina e
clopidogrel após síndrome coronária
aguda
RESUMO 
Introdução: O clopidogrel é um potente
antiplaquetário que necessita de metabo-
lização prévia pelo citocromo (cit) P450.
Vários fármacos são conhecidos por inibir o
cit P450, nomeadamente os inibidores da
bomba de protões (IBPs). Estes são fre-
quentemente associados à dupla anti-agre-
gação plaquetária para prevenção de distúr-
bios pépticos. Estudos in vitro foram os
primeiros a demonstrar inibição da activi-
dade antiplaquetária do clopidogrel pelos
IBPs, enquanto estudos clínicos recentes
levantaram fortes suspeitas quanto à ocor-
rência de eventos clínicos adversos associa-
dos ao uso de IBP com o clopidogrel.
Objectivo: Determinar se a prescrição de um
IBP com dupla anti-agregação se associava
a pior prognóstico após síndrome coronária
aguda (SCA). 
População e métodos: Foram analisados 876
doentes consecutivamente admitidos por
SCA de Janeiro 2004 a Março 2008, e que
tiveram alta medicados com dupla anti-
agregação plaquetária, com uma duração
prevista de seis meses. Foram considerados
apenas os IBP principalmente metaboliza-
dos pelo cit P-450 2C19 e os doentes com
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us to clearly confirm or exclude exposure to
a PPI. Primary end points were six-month
all-cause mortality and the composite of
death, myocardial infarction and unstable
angina at six months.
Results: Of the 802 patients considered for
further analysis, 274 (34.2%) individuals
were medicated with a PPI in addition to
dual antiplatelet therapy. Patients taking
PPIs were older, more often had renal insuf-
ficiency and less often had a history of coro-
nary revascularization and smoking. They
more often presented with Killip class >I
and lower hemoglobin concentration on
admission. There were no significant differ-
ences between the two groups in terms of
medical treatment (during hospital stay and
at discharge) or invasive procedures. By
multivariate analysis, independent and posi-
tive predictors of PPI prescription were
older age and lower hemoglobin concentra-
tion on admission. Patients taking PPIs had
a slightly higher prevalence of six-month
mortality (6.5% vs. 3.9%) and of the com-
posite end point (12.9% vs. 9.2%), although
without statistical significance. By multi-
variate analysis including potential con-
founding variables, the prescription of a PPI
on top of aspirin and clopidogrel was still
not associated with a worse prognosis.
Conclusions: In the present study, PPI pre-
scription in addition to aspirin and clopido-
grel after ACS was not associated with a
worse six-month prognosis.
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informação suficiente disponível nos regis-
tos clínicos e/ou de prescrição. Os doentes
foram classificados em dois grupos de acor-
do com a prescrição de IBP à data da alta.
Os eventos estudados foram a morte por
qualquer causa aos seis meses e o evento
composto de morte, enfarte e angor instável
aos seis meses.
Resultados: Dos 802 doentes incluídos, 274
(34,2%) foram medicados com IBP. Os
doentes medicados com IBP (doentes IBP+)
eram mais idosos, apresentavam com maior
frequência insuficiência renal mas com
menor frequência história tabágica e de
revascularização prévia. Os doentes IBP+
apresentaram-se mais frequentemente em
classe Killip superior a um e com concen-
tração mais baixa de hemoglobina na admis-
são. Não se verificaram diferenças significa-
tivas entre os dois grupos quanto à pre-
scrição médica (durante o internamento ou
após alta) ou ao uso de estratégia invasiva. 
Após análise multivariada, os preditores inde-
pendentes e positivos de prescrição de IBP
foram a idade mais avançada e a concen-
tração mais baixa de hemoglobina na admis-
são. Os doentes medicados com IBP apresen-
taram maior mortalidade aos seis meses
(6,5% versus 3,9%) e maior prevalência do
evento composto aos seis meses (12,9% vs
9,2%), sem no entanto atingir significância
estatística. Após análise multivariada, com
ajuste para os principais preditores de even-
tos clínicos adversos aos seis meses, o uso de
IBP continuou a não apresentar associação
com pior prognóstico aos seis meses.
Conclusão: Na população estudada, o uso de
IBP com dupla anti-agregação plaquetária,
após SCA, não se associou a pior prognósti-
co aos seis meses.
Palavras-chave: 
Síndrome coronária aguda; Inibidor da bomba de pro-
tões; Terapêutica antiplaquetária; Clopidogrel;
Prognóstico
INTRODUCTION
Clopidogrel is a potent antiplatelet agent thatacts through inhibition of the platelet
P2Y12 adenosine diphosphate receptor. In
recen years, treatment with clopidogrel in addi-
tion to aspirin has been proven to reduce cardio-
vascular events after coronary stenting and fol-
lowing the whole spectrum of acute coronary
syndrome (ACS) (1-3).
Clopidogrel is a prodrug converted to its
active metabolite by cytochrome P-450 isoen-
zymes, mainly cytochrome P-450 2C19
(CYP2C19) (4, 5). Numerous drugs are known to
inhibit cytochrome isoenzymes, including pro-
ton pump inhibitors (PPIs). PPIs are frequently
prescribed in combination with antiplatelet
therapy, and particularly dual antiplatelet thera-
py, in order to prevent adverse gastrointestinal
events.
Mechanistic studies, such as the OCLA
study, first suggested that PPIs reduced the
antiplatelet effect of clopidogrel, raising ques-
tions about the clinical significance of this PPI-
clopidogrel interaction (6-8). Recent clinical stud-
ies have also raised concerns that the addition of
a PPI to clopidogrel in ACS patients increases
the risk of recurrent cardiovascular events (9-11).
On the other hand, a preliminary report from the
CREDO trial and a recently published study
based on analysis of data from the TRITON-
TIMI 38 trial found no association between the
addition of a PPI to clopidogrel and an increased
risk of adverse cardiovascular events (12, 13).
Moreover, the results of the COGENT trial,
recently presented by Bhatt et al. at the 21st
Annual Transcatheter Cardiovascular Therapeutics
Conference (TCT, San Francisco, 2009), also
showed no association between PPI use (in addi-
tion to clopidogrel) and a worse prognosis (14).
COGENT is the only randomized trial testing
clopidogrel plus placebo versus clopidogrel plus
omeprazole, in patients taking aspirin and clopi-
dogrel. However, this study was stopped prema-
turely (because of financial issues) and did not
randomize the predicted number of patients.
Consequently, the results may be viewed by
some as underpowered.
Considering these conflicting reports, there
is still some uncertainty about the clinical sig-
nificance of the PPI-clopidogrel interaction.
The aims of our study were to evaluate the
prescription of a PPI in addition to aspirin and
clopidogrel in ACS patients, to compare the
baseline characteristics and therapeutic strate-
gies of patients medicated or not with a PPI, and
finally to determine whether the addition of a
PPI to dual antiplatelet therapy was associated
with a worse outcome.
METHODS
Patients
A total of 876 patients admitted to our coro-
nary care unit with ACS and discharged with
aspirin and clopidogrel, with a planned duration
of at least six months, from January 2004 to
March 2008, were reviewed. ACS diagnosis was
based on symptoms suggestive of ischemia asso-
ciated with electrocardiographic changes (tran-
sient or persistent ST-segment elevation, ST-
segment depression, or T-wave inversion) and/or
elevated levels of myocardial damage biomark-
ers. Patients were classified in two groups
according to whether or not a PPI was associat-
ed with aspirin and clopidogrel at discharge.
Demographic, clinical, laboratory, echocardio-
graphic and angiographic data were collected.
Echocardiographic data refer to the first exam
performed during hospital stay; left ventricular
dysfunction was defined as an ejection fraction
of less than 50%. Angiographic data are from
coronary angiography performed during hospital
stay. Although this was a retrospective cohort
study, all clinical and laboratory data were col-
lected prospectively and recorded in a comput-
erized database, in accordance with our depart-
ment’s protocol for patients admitted to the coro-
nary care unit with ACS.
Proton pump inhibitor use
Treatment with a PPI was at the discretion of
the treating physician. Prescription and clinical
records were used to define exposure to PPI dur-
ing the follow-up period. We first searched for
patients prescribed a PPI at discharge and then
tried to identify those medicated only after dis-
charge (but only during the follow-up period).
We excluded patients with insufficient informa-
tion available on either prescription or clinical
records that could allow us to clearly confirm or 1513
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exclude exposure to a PPI after discharge. The
PPIs considered were those mainly metabolized
by CYP2C19, namely omeprazole, lansoprazole
and rabeprazole. Although pantoprazole can be
metabolized by CYP2C19, it preferentially uses
other routes and consequently was not consid-
ered in our analysis (15). The available data did
not allow us to determine the duration of PPI use
or its exact temporal relation to clinical events.
Follow-up and outcomes
The primary end points were six-month all-
cause mortality and the composite of death,
myocardial infarction and unstable angina at six
months. Follow-up was by telephone interview
and by review of hospital medical records. At six
months, mortality follow-up was complete in
97% of patients, while follow-up for the compos-
ite end point was possible in 92%.
Statistical analysis
The chi-square test was used to compare cat-
egorical variables, expressed as percentages.
Continuous variables, expressed as means ±
standard deviation, were compared using the
Student’s t test for those with a normal distribu-
tion, or the Mann-Whitney test otherwise. As
already stated, the available data did not allow
us to determine the duration of PPI use or its
exact temporal relation to clinical events.
Therefore, a time-varying analysis could not be
performed. In order to avoid significant bias in
the outcome analysis, when considering the
composite end point we decided that patients
with myocardial infarction or unstable angina
occurring before the first identified PPI pre-
scription (during six-month follow-up) would be
excluded from the study. Excluding these
patients could represent a limitation of the
study; however, their inclusion in the PPI group
would mean an even greater bias as the adverse
event would be erroneously attributed to PPI
use. Kaplan-Meier analysis was used to illus-
trate six-month cumulative mortality and com-
posite end point for patients according to PPI
use. The log-rank test was used to test the equal-
ity of the survivor function between the two
groups. Multivariate stepwise logistic regression
analysis was used to identify variables inde-
pendently associated with PPI use, as well as to
determine whether PPI use was independently
associated with a worse six-month prognosis.
The model for six-month overall mortality
included age (per 1 year increase), male gender,
hemoglobin concentration on admission (per 1
g/dl increment), creatinine on admission (above
or below 1.5 g/dl), systolic arterial pressure on
admission (per 1 mmHg increase), history of
myocardial infarction (MI), Killip class >I on
admission, ST-elevation MI, left ventricular sys-
tolic dysfunction and invasive strategy. The
model for the occurrence of the composite event
at six months included age (per 1 year increase),
male gender, diabetes mellitus, creatinine on
admission (above or below 1.5 g/dl), hemoglobin
concentration on admission (per 1 g/dl incre-
ment), previous myocardial infarction (MI), pre-
vious angina pectoris, previous coronary revas-
cularization, Killip class >I on admission, left
ventricular systolic dysfunction and invasive
strategy. All p values were two-sided, and a p
value of less than 0.05 was considered to indi-
cate statistical significance.
RESULTS
Of the 876 patients analyzed, 27 prescribed
pantoprazole and 47 with no available informa-
tion were excluded. Of the remaining 802
patients, 274 (34.2%) were prescribed one of the
PPIs considered and 528 were not prescribed any
PPI during the six-month follow-up. As previous-
ly stated, we compared the latter two groups. Of
patients medicated with a PPI, the drug was pre-
scribed at discharge in 223 patients and during
the follow-up period in 51 of them. None of the 51
patients medicated after discharge had any
adverse cardiovascular event before the first PPI
prescription. Therefore, it was not necessary to
exclude any patient from the analysis.
Baseline characteristics and in-hospital 
management
Baseline characteristics of the patients are
shown in Table I.
Patients prescribed PPIs were older and
more often had renal insufficiency but were less
likely to have a history of smoking and previous
coronary revascularization (surgical or percuta-
neous). No differences were seen regarding
other cardiovascular risk factors and history.1514
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PPI use No PPI use
(n=274) (n=528) p
Age (years) ± SD 65±13 61±13 <0.0001
Male 73.7% 76.7% 0.39
CV risk factors
Diabetes 25.5% 27.1% 0.67%
Hypertension 67.5% 61.4% 0.89%
Hypercholesterolemia 48.5% 49.6% 0.82%
Smoking history 34.7% 43% 0.02
Previous renal insufficiency (GFR <60 ml/min) 28.7% 16.4% <0.0001
CV history
Previous MI 20.1% 20.1% 1.00
Previous angina 14.6% 15.9% 0.68
Previous revascularization 7.3% 12.7% 0.02
Previous stroke 8.4% 4.9% 0.06
STEMI 35% 35% 1.00
At admission
Heart rate (bpm) ± SD 76±19 75±17 0.64
SAP (mmHg) ± SD 138±27 140±26 0.25
Killip class >I 22.4% 14.7% 0.250
Hemoglobin concentration on admission 13.6±1.7 14.1±1.7 < 0.0001
PPI: proton pump inhibitor; SD: standard deviation; CV: cardiovascular; GFR: glomerular filtration rate; MI: myocardial infarction; STEMI: ST-elevation
myocardial infarction; SAP: systolic arterial pressure.
Table I - Baseline characteristics of acute coronary syndrome patients according to PPI use
Patients did not differ regarding the type of pres-
entation of ACS (with or without ST elevation).
On admission, patients prescribed PPIs more
frequently presented with Killip class >I and
with lower hemoglobin concentration.
Treatment strategies, together with echocar-
diographic and angiographic data, and outcomes
are shown in Table II.
There were no differences in medical treat-
ment between the two groups, either during hos-
pital stay or at discharge. There were also no dif-
ferences regarding invasive strategy, severity of
coronary anatomy or percutaneous coronary
revascularization.
As PPI prescription was at the discretion of
the treating physician, we sought to determine
independent predictors of PPI prescription
through multivariate stepwise logistic regression
analysis. Variables considered in the model
were those that showed a statistical association
with PPI use on univariate analysis: age (above
or below 60 years), hemoglobin concentration on
admission (per 1 g/dl increment), creatinine on
admission (above or below 1.5 g/dl), Killip class
>I on admission, previous coronary revascular-
ization and smoking history. Independent and
positive predictors of PPI use were older age and
lower hemoglobin concentration on admission
(Table III).
Clinical outcomes
On univariate analysis, patients prescribed
PPIs had a trend for higher six-month mortality
as well as higher prevalence of the composite
end point at six months (see Figures 1 and 2 for
Kaplan-Meier curves), although these results
did not reach statistical significance. In order to
account for potential confounding factors, we
sought to determine independent predictors of
adverse outcome by multivariate logistic regres-
sion analysis. The models included PPI use
together with all other covariates associated with
six-month adverse events. As shown in Table IV,
PPI use was still not associated with a worse six-
month prognosis. The trend initially observed
was largely explained by differences in baseline
characteristics between the two groups.
Importantly, when considering adverse events,
we found that 96.2% of patients taking PPIs and
97.1% of those not taking PPIs were compliant
for dual antiplatelet therapy at the time of the
recurrent cardiovascular event.
Given the importance of dual antiplatelet
therapy in the context of percutaneous coronary
intervention with stenting, we decided to ana-
lyze the effect of PPI use in this patient group
(n=512). Patients taking PPIs were older and
more often had renal insufficiency and hyper-
tension. On admission, they presented more fre-
quently with Killip class >I and with lower
hemoglobin concentration. No differences were
seen regarding other baseline characteristics
and in-hospital management. On univariate
analysis, patients taking PPIs had a higher
prevalence of the composite end point at six
months (7.7% vs. 2.9%; p=0.03). However, on
multivariate logistic regression analysis with
adjustment for age (per 1 year increase), creati-
nine on admission (above or below 1.5 g/dl),
hemoglobin concentration on admission (per 1
g/dl increment), Killip class >I on admission and
left ventricular systolic dysfunction, PPI use was,
once again, not shown to be an independent pre-
dictor of worse prognosis (Table V). It should be
pointed out that the number of patients considered
was significantly lower than in the main popula-
tion, reducing the statistical power of the analysis.
DISCUSSION
In this retrospective analysis of 802 patients
treated with dual antiplatelet therapy (aspirin
and clopidogrel), we found no association1516
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OR* 95% CI p
Age (above or below 60 years) 1.9 1.2-3.00 0.006
Hemoglobin concentration (per 1 g/dl increment) 0.81 0.71-0.91 <0.0001
Table III. Independent predictors of PPI use
*Adjusted for age (above or below 60 years), hemoglobin concentration on admission (per 1 g/dl increment), creatinine on admission
(above or below 1.5 g/dl), Killip class >I on admission, previous coronary revascularization, smoking history.
PPI use No PPI use
(n=274) (n=528) p
Reperfusion therapy* 63.2% 62.3% 1.00
In-hospital medical therapy
LMWH 96% 95.6% 0.87
GP IIb/IIIa receptor blockers 6.6% 8% 0.57
ACE inhibitor 94.5% 92.6% 0.37
Beta-blocker 90.5% 93.3% 0.16
Statin 99.6% 99.4% 1.00
LVEF <50% 56.8% 55.5% 0.76
Invasive strategy 85.4% 86.9% 0.59
Coronary disease**
Left main or three-vessel disease 17.9% 17.6% 0.92
Left main, three or two-vessel disease with 
LAD involvement 41% 37.7% 0.29
PCI 70.4% 63.6% 0.08
Discharge medical therapy
ACE inhibitor 92% 89.5% 0.31
Beta-blocker 89.1% 92% 0.19
Statin 99.3% 98.7% 0..73
All-cause mortality 6.5% 3.9% 0.11
Composite end point 12.9% 9.2% 0.16
Table II. Treatment, echocardiographic and angiographic data, and outcomes according to PPI use
* Only in patients admitted with ST-elevation myocardial infarction; ** only in patients who underwent coronary angiography
PPI: proton pump inhibitor; LMWH: low molecular weight heparin; GP: glycoprotein; ACE: angiotensin-converting enzyme; LVEF: left ventricular ejec-
tion fraction; LAD: left anterior descending artery; PCI: percutaneous coronary intervention.
between PPI use and worse six-month prognosis
in univariate as well as in multivariate analysis.
Our results are therefore in agreement with
those of O’Donoghue et al. (based on analysis of
the TRITON-TIMI 38 data) and Bhatt et al. (13, 14).
An interesting observation regarding our
data concerns the proportion of patients med-
icated with PPIs. About 34% of our patients
were prescribed a PPI (n=274). This result is in
agreement with those of both Juurlink et al. and 1517
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Figure 1. Kaplan-Meier curve for six-month overall mortality according to PPI use
Figure 2. Kaplan-Meier curve for composite end point at six months according to PPI use
O’Donoghue et al. but contrasts with the 63.9%
of patients taking a PPI in the study conducted
by Ho et al.(8, 9, 13).
In our study, patients prescribed PPIs pre-
sented some differences compared to those not
prescribed PPIs. Patients taking PPIs were
older, more often had renal insufficiency and
less often had a history of smoking and previous
coronary revascularization (surgical or percuta-
neous). They also more frequently presented
with Killip class >I and with lower hemoglobin
concentration on admission. No differences were
seen regarding the other baseline characteristics
and in-hospital management, including medical
treatment, invasive procedures and echocardio-
graphic and angiographic data. Interestingly,
and by chance, since PPI use was not random-
ized, the differences between patients taking
PPIs and those not taking PPIs were not as pro-
nounced as those reported by other authors (9-11).
This could have reduced confounding in the out-
come analysis.
One important issue when investigating
potential interactions between PPIs and clopi-
dogrel is the concomitant use of aspirin. We
decided to evaluate patients strictly on dual
antiplatelet therapy for two main reasons. First,
in day-to-day practice, clopidogrel is essentially
prescribed on top of aspirin (in the context of
dual antiplatelet therapy), monotherapy being
mainly reserved for the few patients unable to
take aspirin, because of hypersensitivity or
major gastrointestinal intolerance. Second, we
intended to reduce the potential confounding of
lack of aspirin when analyzing the PPI-clopido-
grel interaction. As pointed out above, when
considering adverse events in our population,
96.2% of the patients taking PPIs and 97.1% of
those not taking PPIs were compliant for dual
antiplatelet therapy at the time of the adverse
cardiovascular event. These results did not favor
potential confounding by non-compliance to
either antiplatelet drug. Inadequate information
on concurrent aspirin use was one of the limita-1518
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Six-month all-cause mortality
OR* 95% CI p
PPI use 1.04 0.49-2.18 0.91
Age (per 1 year increment) 1.08 1.03-1.13 <0.0001
Hemoglobin concentration (per 1 g/dl increment) 0.75 0.6-0.93 0.008
SAP (per 1 mmHg increment) 1.02 1.01-1.03 0.019
Killip class >I on admission 2.47 1.14-5.29 0.02
Composite end point at six months
OR** 95% CI p
PPI use 1.1 0.64-1.9 0.71
Age (per 1 year increment) 1.07 1.03-1.08 <0.0001
Hemoglobin concentration (per 1 g/dl increment) 0.79 0.67-0.93 0.003
Previous coronary revascularization 2.87 1.41-5.81 <0.0001
Left ventricular systolic dysfunction 3.44 1.8-6.54 0.003
Table IV. Independent predictors of adverse outcome
PPI: proton pump inhibitor; SAP: systolic arterial pressure
* Adjusted for age (per 1 year increase), male gender, hemoglobin concentration on admission (per 1 g/dl increment), creatinine on
admission (above or below 1.5 g/dl), systolic arterial pressure on admission (per 1 mmHg increase), previous myocardial infarction
(MI), Killip class >I on admission, ST-elevation MI, left ventricular systolic dysfunction and invasive strategy.
** Adjusted for age (per 1 year increase), male gender, diabetes, creatinine on admission (above or below 1.5 g/dl), hemoglobin con-
centration on admission (per 1 g/dl increment), previous myocardial infarction (MI), previous angina, previous coronary revasculariza-
tion, Killip class >I on admission, left ventricular systolic dysfunction and invasive strategy.
OR* 95% CI p
PPI use 2.09 0.79-5.48 0.13
Age (per 1 year increment) 1.07 1.02-1.11 0.003
Left ventricular (systolic dysfunction 5.02 1.42-17.74 0.01
Table V. Independent predictors of adverse outcome – composite end point at six months (patients undergoing percutaneous coronary
intervention)
PPI: proton pump inhibitor
* Adjusted for age (per 1 year increase), hemoglobin concentration on admission (per 1 g/dl increment), creatinine on admission
(above or below 1.5 g/dl), Killip class >I on admission and left ventricular systolic dysfunction.
tions of some previously released observational
data and was rapidly identified as a likely expla-
nation for the higher event rate in patients using
PPIs (9).
Another important issue in the evaluation of
a potential clinically significant PPI-clopidogrel
interaction is compliance with antiplatelet ther-
apy. Patients’ compliance is much better in the
setting of randomized controlled trials, which
makes the results from TRITON-TIMI 38 and
COGENT more reliable regarding this issue.
Although our study was observational, the
majority of patients analyzed were followed after
discharge in our department, and the impor-
tance of compliance with antiplatelet therapy
was systematically transmitted to all of them.
The results of studies so far are conflicting.
However, the harmful effects described by the
first observational studies can no longer be
taken as fact.
As most experts have pointed out, the only
way to definitely establish the clinical signifi-
cance of the PPI-clopidogrel interaction would
be a randomized trial. Such a trial, COGENT,
was under way until recently. It was intended to
randomize 5000 patients to clopidogrel plus
placebo versus clopidogrel plus omeprazole;
patients were to be treated with clopidogrel for
at least twelve months. Unfortunately, the trial
was stopped prematurely by the sponsor due to
financial issues, after 3627 patients had been
enrolled. Nonetheless, the results were recently
released by Bhatt et al. at the 21st Annual TCT
Conference (2009) (14). No association between
PPI use (in addition to clopidogrel) and worse
prognosis was found, while fewer bleeding com-
plications were reported in the omeprazole
group. However, as stated, the COGENT trial
did not randomize the predicted number of
patients, and consequently the results may be
viewed by some as underpowered.
It should be remembered that this is not the
first time that attenuation of clopidogrel’s effect
demonstrated ex vivo has failed to translate into
clinical significance, namely worse outcomes. In
mechanistic studies, atorvastatin was shown to
attenuate clopidogrel’s platelet inhibitory effect(16).
However, subsequent clinical studies, based on
analysis of randomized trials, did not report an
association with worse clinical outcomes (17, 18).
This, as well as the present study with PPIs, is a
reminder that ex-vivo studies, such as platelet
assays, and observational data are not equiva-
lent to randomized controlled trials.
LIMITATIONS
There are several limitations to be consid-
ered in the interpretation of our study. First, this
was a retrospective observational and non-ran-
domized study conducted at a single hospital,
and as such, both identified and unidentified
confounders may have influenced the outcomes.
For instance, we could not assess CYP2C19
polymorphisms, the concomitant prescription of
other drugs metabolized by CYP2C19, or the
existence of gastrointestinal pathology that
could have influenced both PPI treatment and
outcomes. Second, the number of patients stud-
ied was limited, particularly compared with
other studies evaluating the same issue (9-14).
Third, PPI use was determined through the con-
sultation of prescription and clinical records
that could be incomplete. Finally, as previously
stated, the duration of PPI use and its exact tem-
poral relation to clinical events could not be
determined from the available data, and conse-
quently, a time-varying analysis could not be
performed.
CONCLUSIONS
In our study, PPI use among ACS patients
treated with dual antiplatelet therapy (aspirin
and clopidogrel) was not associated with a worse
six-month prognosis. Our results back up those
recently presented by O’Donoghue et al. and
Bhatt et al. (13, 14).
Although some uncertainty may remain, the
evidence gathered so far favors the lack of a
clinically significant detrimental effect of the
combination of a PPI with clopidogrel and
aspirin, as all the data derived from randomized
trials showed no significant association between
PPI use and worse outcomes (12-14).
One interesting way to approach this issue
would be a randomized controlled trial combin-
ing both platelet assays and clinical results. In
this way, the potential inhibition of clopidogrel’s
antiplatelet effect by PPI could be matched 1519
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with the occurrence (or otherwise) of clinical
events.
Furthermore, and despite some uncertainty
that may remain, recently presented results raise
the question whether the statements released by
the European Medicines Agency and the Food
and Drug Administration were too premature and
perhaps too strong, soon after the publication of
the very first observational studies(19, 20).
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